Centene's Marketplace Book Shrank 41 Percent. Its Risk-Adjustment Position Swung Favorable With It

Centene's consolidated health benefits ratio fell to 89.6% in the second quarter of 2026 from 93.0% a year earlier, GAAP net income swung to $1.1 billion from a $253 million loss, and full-year adjusted earnings guidance rose to more than $4.80 per share from more than $3.40 (Centene, July 28, 2026). Marketplace membership fell to 3.5 million from 5.9 million over the same twelve months, and management now expects a meaningful risk-adjustment receivable rather than the shortfall it warned shareholders about a year earlier.

Those two facts, a shrinking book and an improving risk-adjustment position, are not a coincidence sitting next to each other in the same earnings release. They are the same mechanism working in one direction after working in the opposite direction twelve months earlier. In July 2025, Centene withdrew its full-year guidance after Wakely claims data showed marketplace morbidity running well above its pricing assumptions, a miss the company said would cost $1.8 billion in risk-adjustment revenue and $2.75 per share, and the stock fell more than 32% in premarket trading the day it disclosed the news (Becker's Payer Issues, July 2025; Centene, July 1, 2025). A year later, the same Wakely-informed process, now reading June 2026 claims data, has flipped: CEO Sarah London attributed the improved outlook to "underlying business strengths and a more fully informed view of our Marketplace risk adjustment positioning" (Sarah London, Centene Q2 2026 earnings call, July 28, 2026), while CFO Drew Asher described the 2026 Marketplace risk-adjustment position as a "meaningful receivable" rather than the roughly neutral-to-payable position the company had guided to earlier in the year (Drew Asher, Centene Q2 2026 earnings call, July 28, 2026).

The Segment-Level Numbers

The consolidated 89.6% health benefits ratio blends three segments moving at different speeds. Medicaid came in at 93.9%, improved from 94.9% a year earlier, even as Centene lost more than 700,000 Medicaid members over the same period; the company credits states raising capitation rates to better align payment with the acuity of a post-redetermination Medicaid population (Healthcare Dive, July 2026). Medicare came in at 89.5%, aided by favorable resolution of 2025 programmatic items that management does not expect to recur. Commercial, which is almost entirely the ACA Marketplace book, posted a 79.2% ratio, improved sharply from 90.6% in the second quarter of 2025, an 11.4-point swing that is the single largest driver of the consolidated improvement.

An 11.4-point improvement in a health benefits ratio inside twelve months is not the kind of movement that ordinary rate action or medical-cost management produces on its own. Rate increases move a ratio by low single digits in a year; a swing this size points to a change in the composition of who is being priced, not just what they are being charged.

Why a Smaller Book Can Mean a Sicker Average Member

The Marketplace membership decline is not a story about healthy people shopping elsewhere. Nationally, the Department of Health and Human Services estimates improper, phantom, and fraudulent Marketplace enrollment peaked at 5.6 million people in 2025 and has been cut to roughly 2.6 million for 2026 through stepped-up income and eligibility verification, part of why national Marketplace enrollment fell to 19.2 million by February 2026 (ASPE/HHS, June 2026). actuary.info covered the mechanics of that purge in detail when the enrollment numbers first landed, including HHS's own framing that the drop reflected fraud removal rather than attrition (see actuary.info's coverage of the 2026 effectuated enrollment purge). A phantom enrollee, someone auto-enrolled by an agent without authorization or dually covered under Medicaid, generates essentially no claims. Removing that person from the denominator does not change total claims dollars; it removes a zero-cost member from the pool used to calculate the average, which mechanically raises average morbidity even if the health status of every remaining individual member is unchanged.

Centene's own numbers are consistent with a book that lost low-cost members disproportionately rather than a book that lost members evenly. Marketplace membership held "reasonably stable" at 3.5 million between the first and second quarters of 2026, with management flagging additional attrition later in the year as CMS eligibility-verification steps continue to work through the book (Drew Asher, Centene Q2 2026 earnings call, July 28, 2026). That stability inside the quarter, paired with the acuity improvement showing up in the risk-adjustment data, points toward a book where the removal already happened earlier in the enrollment cycle and the retained population is now the steadier, higher-acuity core that survived verification.

The Risk-Adjustment Transfer Mechanic

The HHS risk-adjustment program is not a subsidy from the government to insurers; it is a zero-sum transfer among ACA-compliant plans within the same state and market. CMS calculates a risk score for each plan's enrolled population using diagnosis codes mapped to Hierarchical Condition Categories, compares that score to the statewide average, and moves money from plans with lower-than-average risk scores to plans with higher-than-average risk scores, funded by a $0.20 per-member-per-month user fee CMS finalized for the 2026 benefit year (CMS, 2026 benefit year). A carrier's transfer position is therefore relative, not absolute: what matters is not how sick Centene's members are in isolation, but how sick they are compared with the statewide average across every other ACA-compliant issuer in that market.

That relative structure is exactly why a purge of low-acuity phantom enrollees can turn a risk-adjustment position favorable even without any change in the health status of real members. If the removed enrollees were disproportionately low-risk, both Centene's own risk score and the statewide average risk score rise, but Centene's retained population, already skewing toward the Silver-tier, higher-HCC-coded enrollees who tend to stay engaged with coverage, can end up rising faster than the market average it is being compared against. Centene told analysts that June 2026 Wakely claims data confirmed its retained Silver membership carries elevated diagnoses in chronic disease, anti-inflammatory drug use, and oncology categories with what the company described as robust HCC coding, supporting the shift from a roughly neutral 2026 outlook to a receivable position (Drew Asher, Centene Q2 2026 earnings call, July 28, 2026). The transfer does not arrive with the premium. It settles on a lag: the final 2025 benefit-year reconciliation landed in the second quarter of 2026, more than a year after the coverage it measures was sold, which is the structural reason a risk-adjustment swing shows up as a discrete quarterly item rather than smoothing into the ratio as premium is earned.

Sizing the Swing: $481 Million In, $180 Million Net

The dollar mechanics behind the favorable print are more layered than a single number. Centene recognized $481 million of favorable impact from the final 2025 CMS risk-adjustment reconciliation across the first half of 2026 (Healthcare Dive, July 2026). Roughly $250 million of that had already been embedded in the company's recurring margin estimate before the reconciliation landed, and other adjustments absorbed a further slice, leaving $180 million of net favorable development relative to prior guidance, worth approximately 60 basis points of full-year margin. Asher was explicit on the earnings call that roughly $0.50 of the quarter's earnings per share came from 2025 items management does not expect to recur in 2027, a distinction that matters for anyone modeling forward margin off this quarter's reported number rather than off the recurring run rate underneath it.

What the Guidance Raise Assumes for the Second Half

Centene's full-year Marketplace pre-tax margin outlook moved to 4.5% to 5% from a prior 3%, and the company's guidance raise leans on more than the risk-adjustment reconciliation alone. Management pointed to utilization among Silver-tier members moderating in the second quarter relative to the elevated trend baked into first-quarter guidance, a signal that second-half medical cost trend is expected to track closer to the original pricing assumption than the more conservative revision management had been carrying. That is a meaningfully different claim from "the risk-adjustment check solved the problem." It is a claim that both legs, a favorable risk-adjustment settlement on 2025 business and a moderating trend line on 2026 business, are moving the same direction at the same time. If either leg reverses in the third or fourth quarter, closer to $0.50 of the raised guidance sits on a non-recurring settlement rather than on the underlying trend Centene is now pricing forward.

Pricing 2027 Rates Against a Book That Recomposed Mid-Year

The actuarial complication sits one filing cycle ahead. Insurers set 2027 Marketplace rates in filings due through the summer of 2026, before the full effect of 2026's enrollment purge and the accompanying risk-adjustment reconciliation was known with certainty, and early 2027 filings already show statewide average increases ranging from 6.5% in Vermont to 22.4% in Washington, driven substantially by insurers' own morbidity assumptions about who remains in the pool after subsidy-driven and program-integrity-driven attrition (Georgetown University Center on Health Insurance Reforms, 2026). MVP Health Plan of Vermont quantified the morbidity effect of continued subsidy expiration at an additional $48 per member per month in projected claims cost, and Fallon Community Health Plan of Massachusetts attributed 3.3 points of its 25.7% requested increase specifically to morbidity shifts tied to expired enhanced premium tax credits. actuary.info examined the same filing cycle's handling of cost-sharing reduction assumptions in its coverage of CSR loading returning to the 2027 actuarial memorandum.

A pricing actuary setting those 2027 rates faces a book that recomposed twice inside eighteen months, once through the 2025 morbidity miss that forced the guidance withdrawal, and again through 2026's program-integrity purge, with the risk-adjustment true-up for the current recomposition not fully known until the 2026 benefit-year reconciliation lands in mid-2027. Pricing off a retained population's observed morbidity assumes that population is stable going forward; Centene's own disclosure that it expects further attrition later in 2026 from ongoing eligibility verification means the population an actuary is pricing against in a 2027 filing may not be the same population that generates the 2027 risk-adjustment settlement. That gap between the pricing snapshot and the settlement population is exactly the kind of assumption risk that produced the 2025 miss in the first place, just running in the opposite direction this time.

A Different Mechanism Than the Medicaid MLR Story

It is worth separating this from the Medicaid managed-care read that dominated the broader sector's Q2 print. Molina reported a 92.7% Medicaid MLR that some read as a cycle bottom, a call resting on state rate adequacy catching up to redetermination-driven acuity shifts inside a program funded through state capitation rates set in advance of the coverage year (see actuary.info's analysis of Molina's Medicaid MLR trough call). Centene's Marketplace story runs on an entirely different funding mechanism: CMS risk adjustment is a market-wide, backward-looking transfer settled well after the coverage year closes, not a state's forward-priced capitation rate. Both mechanisms respond to the same underlying driver, a population getting sicker on average as lower-acuity members exit, but Medicaid's fix arrives through the next rate-setting cycle while Marketplace's fix arrives through a reconciliation payment on a lag of more than a year. Conflating the two risks assuming Centene's Marketplace recovery is as structurally durable as a state capitation reset, when it is closer to a claims-driven settlement that could reverse if the retained population's composition shifts again before 2027.

What to Watch Into the Third Quarter

The next data points that will separate a durable acuity shift from a one-time reconciliation catch-up are the pace of further Marketplace attrition as CMS verification continues through the back half of 2026, whether the moderating Silver-tier utilization trend management flagged holds through the third quarter, and how the 2026 benefit-year risk-adjustment position, still an estimate until CMS's interim report and eventual final reconciliation, compares with the "meaningful receivable" management is now guiding toward. A repeat of the 2025 pattern, where an early-year read proved directionally wrong once fuller claims data arrived, would not be unprecedented for this specific company on this specific program; it is the same Wakely-informed process that missed low a year ago now reading high, and the honest read of Centene's Q2 print is that the mechanism generating both outcomes, a relative, lagged, market-wide transfer settled against a population whose composition keeps changing, has not gotten any less sensitive to enrollment volatility than it was in July 2025.